Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity

Impact of Extra Virgin Olive Oil Oleocanthal Content on Platelet Reactivity in Healthy Humans

Sponsors

Lead Sponsor: University of California, Davis

Collaborator: USDA, Western Human Nutrition Research Center

Source University of California, Davis
Brief Summary

Data from limited dietary intervention trials suggest that the cardiovascular health benefit of extra virgin olive oil (EVOO) may increase with phenolic content. However, while EVOOs contain an array of bioactive compounds, little information exists regarding the physiological effects of specific chemical species. Among the EVOO-derived phenolics with demonstrated anti-inflammatory effects in animal and in vitro models is oleocanthal, an inhibitor of cyclooxygenase (COX). The current study compared the impact of acute intake (40 mL) of EVOO on platelet reactivity in healthy adult males (n=9). The volunteers were randomly assigned to consume three EVOOs in a double-blind controlled trial. The EVOO were characterized and chosen for equivalency in their total phenolic content and fatty acid profiles, but differing in their oleocanthal to oleacein ratio.

Detailed Description

Ten healthy adult males (20-50 years of age) will be enrolled into a randomized triple-blind, controlled crossover study that will test the acute effects of oleocanthal-rich extra virgin olive oil intake on platelet aggregation. Each participant will be asked to participate in four study days, separated by at least 1-week, in which they will be randomized to consume on each study day 40 mL (~3 tablespoons) of either oleocanthal-rich extra virgin olive oil (OO), or an extra virgin OO that is matched in total phenolics but oleocanthal-poor, or a refined OO that is low in all phenolics In addition to the oils, on a fourth study day visit, after completion of the study visits involving oil intake the subjects will be asked to take 400mg of ibuprofen.

Collection procedures will be performed at the same time of the day to avoid circadian effects. A blood sample (50 mL ~ 3.5 tbsp) will be collected for the measurement of platelet aggregometry and COX metabolites. Following this initial blood draw, the subjects will consume their assigned test product for the day. Two-hours following the intake of the assigned olive oil, a second blood sample will be drawn (50 mL ~ 3.5 tbsp). After the second blood draw, the study day will be complete.

Overall Status Completed
Start Date January 2015
Completion Date September 2015
Primary Completion Date September 2015
Phase N/A
Study Type Interventional
Primary Outcome
Measure Time Frame
Optical Platelet Aggregometry Change from baseline 2 hours post intake
Secondary Outcome
Measure Time Frame
Activated Platelet Oxylipin Production Change from baseline 2 hours post intake
Enrollment 9
Condition
Intervention

Intervention Type: Other

Intervention Name: D2i2

Description: Oleocanthal provided in a 2:1 ratio compared to oleacein

Arm Group Label: Oleocanthal-rich, D2i2

Other Name: Oleocanthal-rich

Intervention Type: Other

Intervention Name: D2i0.5

Description: Oleocanthal provided in a 1:2 ratio compared to oleacein

Arm Group Label: Oleacein-rich, D2i0.5

Other Name: Oleocanthal-low

Intervention Type: Other

Intervention Name: D2i0

Description: No oleocanthal and no oleacein

Arm Group Label: Oleocanthal and Oleacein-low, D2i0

Other Name: Control EVOO

Intervention Type: Drug

Intervention Name: Ibuprofen

Description: 400 mg of Ibuprofen

Arm Group Label: Ibuprofen

Eligibility

Criteria:

Inclusion Criteria:

- Willing and able to comply with study protocols

- Willing to drink 2 tablespoons of olive oil

- BMI 18.5 to 30 kg/m2

- Weight ≥ 110 pounds

Exclusion Criteria:

- Adults who are not able to consent

- BMI ≥ 31 kg/m2

- Under current medical supervision

- Self-reported daily use of drugs that are known to affect platelet function, such as aspirin, Excedrin, and NSAIDS

- Ibuprofen intolerance or allergy

- Cannot speak English

- Allergy to olives or olive oil

- Vegetarian, Vegan, food faddists, individuals using non-traditional diets, on a weight loss diet or individual following diets with significant deviations from the average diet of the general population.

- A history of cardiovascular disease, stroke, cancer, renal, hepatic, or thyroid disease, GI tract disorders, previous GI surgery

- Currently taking prescription drugs or supplements

- Indications of substance or alcohol abuse within the last 3 years

- Not willing to stop any supplement use, including herbal, plant or botanical, fish oil, oil supplements.

- Not willing to refrain from olive oil consumption.

- Blood Pressure ≥ 140/90 mmHg

- Self-reported malabsorption

- Metabolic panel results or complete blood counts that are outside of the normal reference range.

- Screening LDL ≥ 190 mg/dl for those who have 0 - 1 major risk factors apart from LDL cholesterol [(i.e. family history of premature coronary artery disease (male first degree relative < 55 years; CHD in female first degree relative < 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL].

- Screening LDL ≥ 160 mg/dl for those who have 2 major risk factors apart from LDL cholesterol [(i.e. family history of premature coronary artery disease (male first degree relative < 55 years; CHD in female first degree relative < 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL].

- Screening LDL ≥ than 130 mg/dl for those who have 2 major risk factors apart from LDL cholesterol ((i.e. family history of premature coronary artery disease (male first degree relative < 55 years; CHD in female first degree relative < 65 years), cigarette smoker, HDL-C ≤ 40 mg/dL), and a Framingham 10 - year Risk Score 10 - 20 % (using NCEP calculator).

- Current enrollee in a clinical research study.

- Individuals with blood clotting or platelet defect disorders

Gender: Male

Minimum Age: 20 Years

Maximum Age: 50 Years

Healthy Volunteers: Accepts Healthy Volunteers

Overall Official
Last Name Role Affiliation
Roberta R Holt, PhD Principal Investigator University of California, Davis
Verification Date

October 2019

Responsible Party

Type: Sponsor

Keywords
Has Expanded Access No
Condition Browse
Number Of Arms 4
Arm Group

Label: Oleocanthal-rich, D2i2

Type: Experimental

Description: Oleocanthal-rich, D2i2 (Extra virgin olive oil containing oleocanthal to oleacein in a 2:1 ratio)

Label: Oleacein-rich, D2i0.5

Type: Experimental

Description: Oleacein-rich, D2i0.5 (Extra virgin olive oil containing oleocanthal to oleacein in a 1:2 ratio)

Label: Oleocanthal and Oleacein-low, D2i0

Type: Placebo Comparator

Description: Oleocanthal and Oleacein-low, D2i0 (Extra virgin olive oil containing low amounts of oleocanthal to oleacein, but with a similar total phenolic content as the other two oils)

Label: Ibuprofen

Type: Active Comparator

Description: Ibuprofen, 400 mg

Patient Data No
Study Design Info

Allocation: Randomized

Intervention Model: Crossover Assignment

Primary Purpose: Prevention

Masking: Double (Participant, Investigator)

Masking Description: All participants received all four interventions in a randomized, cross-over design in which both participant and caregiver were masked to the assignment (with the exception of the fourth intervention, ibuprofen, which was always administered at the final study visit).

Source: ClinicalTrials.gov